The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.
For details about CAPS-UK, and the conditions you agree to be bound by, please see our Terms and Conditions.
This page brought to you by USEQ\WEB22.
Recs
ZFN technology is about to pop. It's incredible what they are able to do. This is just the start and SGMO is in a good position for a takeout or major partnership when it hits.